Elucidating the interplay between IgG-Fc valency and FcγR activation for the design of immune complex inhibitors

Science Translational Medicine

Volumn 8, Issue 365, 2016, Pages

  Ortiz, Daniel F ^a   Lansing, Jonathan C ^a   Rutitzky, Laura ^a   Kurtagic, Elma ^a   Prod'homme, Thomas ^a   Choudhury, Amit ^a   Washburn, Nathaniel ^a   Bhatnagar, Naveen ^a   Beneduce, Christopher ^a   Holte, Kimberly ^a   Prenovitz, Robert ^a   Child, Matthew ^a   Killough, Jason ^a   Tyler, Steven ^a   Brown, Julia ^a   Nguyen, Stephanie ^a   Schwab, Inessa ^b   Hains, Maurice ^a   Meccariello, Robin ^a   Markowitz, Lynn ^a   Wang, Jing ^a   Zouaoui, Radouane ^a   Simpson, Allison ^a   Schultes, Birgit ^a   Capila, Ishan ^a   Ling, Leona ^a   Nimmerjahn, Falk ^b   Manning, Anthony M ^a   Bosques, Carlos J ^a   more..

^a Momenta Pharmaceuticals Inc   (United States)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN FC3Y FRAGMENT; IMMUNOMODULATING AGENT; INTERLEUKIN 8; UNCLASSIFIED DRUG; AUTOANTIBODY; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CELL PHAGOCYTOSIS; COLLAGEN-INDUCED ARTHRITIS; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG DESIGN; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; EPIDERMOLYSIS BULLOSA ACQUISITA; HUMAN; HUMAN CELL; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION; THROMBOCYTE ACTIVATION; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN ANTIBODY COMPLEX; ARTHRITIS; C57BL MOUSE; CELL LINE; CYTOLOGY; DRUG EFFECTS; EXPERIMENTAL ARTHRITIS; IMMUNE COMPLEX DISEASE; IMMUNOLOGY; MONOCYTE; PHAGOCYTE; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGEN-ANTIBODY COMPLEX; ARTHRITIS; ARTHRITIS, EXPERIMENTAL; AUTOANTIBODIES; AUTOIMMUNE DISEASES; CELL LINE; EPIDERMOLYSIS BULLOSA ACQUISITA; HUMANS; IMMUNE COMPLEX DISEASES; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; MALE; MICE; MICE, INBRED C57BL; MONOCYTES; PHAGOCYTES; PLATELET ACTIVATION; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, IGG; SIGNAL TRANSDUCTION;

EID: 84995588278     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaf9418     Document Type: Article

References (58)

1. C. A. Janeway Jr, P. Travers, M. Walport, M. J. Shlomchik, in Immunobiology, 5th edition: The Immune System in Health and Disease (Garland Science, ed. 5, 2001).
2. P. Sondermann, R. Huber, V. Oosthuizen, U. Jacob, The 3.2-Å crystal structure of the human IgG1 Fc fragment-FcgRIII complex. Nature 406, 267-273 (2000).
3. J. V. Ravetch, S. Bolland, IgG Fc receptors. Ann. Rev. Immunol. 19, 275-290 (2001).
4. K. Maenaka, P. A. van der Merwe, D. I. Stuart, E. Y. Jones, P. Sondermann, The human low affinity Fcg receptors IIa, IIb, and III bind IgG with fast kinetics and distinct thermodynamic properties. J. Biol. Chem. 276, 44898-44904 (2001).
5. S. Ghazizadeh, J. B. Bolen, H. B. Fleit, Tyrosine phosphorylation and association of Syk with FcgRII in monocytic THP-1 cells. Biochem. J. 305 (Pt. 2), 669-674 (1995).
6. R. K. Park, Y. Liu, D. L. Durden, A role for Shc, Grb2, and Raf-1 in FcgRI signal relay. J. Biol. Chem. 271, 13342-13348 (1996).
7. D. D. Billadeau, P. J. Leibson, ITAMs versus ITIMs: Striking a balance during cell regulation. J. Clin. Invest. 109, 161-168 (2002).
8. F. Nimmerjahn, J. V. Ravetch, Fcg receptors as regulators of immune responses. Nat. Rev. Immunol. 8, 34-47 (2008).
9. K. G. C. Smith, M. R. Clatworthy, FcgRIIB in autoimmunity and infection: Evolutionary and therapeutic implications. Nat. Rev. Immunol. 10, 328-343 (2010).
10. P. Bruhns, Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119, 5640-5649 (2012).
11. X. Li, A. W. Gibson, R. P. Kimberly, Human FcR polymorphism and disease. Curr. Top. Microbiol. Immunol. 382, 275-302 (2014).
12. S. B. Clarkson, J. B. Bussel, R. P. Kimberly, J. E. Valinsky, R. L. Nachman, J. C. Unkeless, Treatment of refractory immune thrombocytopenic purpura with an anti-Fcg-receptor antibody. N. Engl. J. Med. 314, 1236-1239 (1986).
13. M. M. Flaherty, T. K. MacLachlan, M. Troutt, T. Magee, N. Tuaillon, S. Johnson, K. E. Stein, E. Bonvini, R. Garman, L. Andrews, Nonclinical evaluation of GMA161 - An antihuman CD16 (FcgRIII) monoclonal antibody for treatment of autoimmune disorders in CD16 transgenic mice. Toxicol. Sci. 125, 299-309 (2012).
14. R. M. Anthony, F. Nimmerjahn, D. J. Ashline, V. N. Reinhold, J. C. Paulson, J. V. Ravetch, Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 320, 373-376 (2008).
15. M. Debré, M.-C. Bonnet, W. H. Fridman, E. Carosella, N. Philippe, P. Reinert, E. Vilmer, C. Kaplan, J.-L. Teillaud, C. Griscelli, Infusion of Fcg fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 342, 945-949 (1993).
16. C.-H. Hsu, M.-R. Chen, F.-Y. Hwang, H.-A. Kao, H.-Y. Hung, C.-H. Hsu, Efficacy of plasmintreated intravenous gamma-globulin for therapy of Kawasaki syndrome. Pediatr. Infect. Dis. J. 12, 509-512 (1993).
17. J. L. Teeling, T. Jansen-Hendriks, T. W. Kuijpers, M. de Haas, J. G. J. van de Winkel, C. E. Hack, W. K. Bleeker, Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: Studies in experimental immune thrombocytopenia. Blood 98, 1095-1099 (2001).
18. V. Siragam, D. Brinc, A. R. Crow, S. Song, J. Freedman, A. H. Lazarus, Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease? J. Clin. Invest. 115, 155-160 (2005).
19. R. Bazin, R. Lemieux, T. Tremblay, I. St-Amour, Tetramolecular immune complexes are more efficient than IVIg to prevent antibody-dependent in vitro and in vivo phagocytosis of blood cells. Br. J. Haematol. 127, 90-96 (2004).
20. A. Jain, H. S. Olsen, R. Vyzasatya, E. Burch, Y. Sakoda, E. Y. Mérigeon, L. Cai, C. Lu, M. Tan, K. Tamada, D. Schulze, D. S. Block, S. E. Strome, Fully recombinant IgG2a Fc multimers (stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenic purpura in mice. Arthritis Res. Ther. 14, R192 (2012).
21. Y. Hashimoto, E. R. Hurd, Human neutrophil aggregation and increased adherence to human endothelial cells induced by heat-aggregated IgG and immune complexes. Clin. Exp. Immunol. 44, 538-547 (1981).
22. M. Schattner, M. Lazzari, A. S. Trevani, E. Malchiodi, A. C. Kempfer, M. A. Isturiz, J. R. Geffner, Activation of human platelets by immune complexes prepared with cationized human IgG. Blood 82, 3045-3051 (1993).
23. J. K. Voice, P. J. Lachmann, Neutrophil Fcg and complement receptors involved in binding soluble IgG immune complexes and in specific granule release induced by soluble IgG immune complexes. Eur. J. Immunol. 27, 2514-2523 (1997).
24. A. Lux, X. Yu, C. N. Scanlan, F. Nimmerjahn, Impact of immune complex size and glycosylation on IgG binding to human FcgRs. J. Immunol. 190, 4315-4323 (2013).
25. L. P. Ganesan, G. Wei, R. A. Pengal, L. Moldovan, N. Moldovan, M. C. Ostrowski, S. Tridandapani, The serine/threonine kinase Akt promotes Fcg receptor-mediated phagocytosis in murine macrophages through the activation of p70S6 kinase. J. Biol. Chem. 279, 54416-54425 (2004).
26. I. Schwab, F. Nimmerjahn, Intravenous immunoglobulin therapy: How does IgG modulate the immune system? Nat. Rev. Immunol. 13, 176-189 (2013).
27. S. Tridandapani, K. Siefker, J.-L. Teillaud, J. E. Carter, M. D. Wewers, C. L. Anderson, Regulated expression and inhibitory function of FcgRIIb in human monocytic cells. J. Biol. Chem. 277, 5082-5089 (2002).
28. P. M. Hogarth, G. A. Pietersz, Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat. Rev. Drug Discov. 11, 311-331 (2012).
29. F. Liao, H. S. Shin, S. G. Rhee, Tyrosine phosphorylation of phospholipase C-g1 induced by cross-linking of the high-affinity or low-affinity Fc receptor for IgG in U937 cells. Proc. Natl. Acad. Sci. U.S.A. 89, 3659-3663 (1992).
30. J. A. Odin, J. C. Edberg, C. J. Painter, R. P. Kimberly, J. C. Unkeless, Regulation of phagocytosis and [Ca2+]i flux by distinct regions of an Fc receptor. Science 254, 1785-1788 (1991).
31. J. B. B. Ridgway, L. G. Presta, P. Carter, 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 9, 617-621 (1996).
32. K. Gunasekaran, M. Pentony, M. Shen, L. Garrett, C. Forte, A. Woodward, S. B. Ng, T. Born, M. Retter, K. Manchulenko, H. Sweet, I. N. Foltz, M. Wittekind, W. Yan, Enhancing antibody Fc heterodimer formation through electrostatic steering effects: Applications to bispecific molecules and monovalent IgG. J. Biol. Chem. 285, 19637-19646 (2010).
33. I. Mellman, H. Plutner, Internalization and degradation of macrophage Fc receptors bound to polyvalent immune complexes. J. Cell Biol. 98, 1170-1177 (1984).
34. P. Bruhns, F. Jönsson,Mouse and human FcR effector functions. Immunol. Rev. 268, 25-51 (2015).
35. J. Qiao, M. Al-Tamimi, R. I. Baker, R. K. Andrews, E. E. Gardiner, The platelet Fc receptor, FcgRIIa. Immunol. Rev. 268, 241-252 (2015).
36. A. Mittag, D. Lenz, A. O. H. Gerstner, U. Sack, M. Steinbrecher, M. Koksch, A. Raffael, J. Bocsi, A. Tárnok, Polychromatic (eight-color) slide-based cytometry for the phenotyping of leukocyte, NK, and NKT subsets. Cytometry A 65, 103-115 (2005).
37. H. Leong, J. Stachnik, M. E. Bonk, K. A. Matuszewski, Unlabeled uses of intravenous immune globulin. Am. J. Health Syst. Pharm. 65, 1815-1824 (2008).
38. M. Marino, M. Ruvo, S. De Falco, G. Fassina, Prevention of systemic lupus erythematosus in MRL/lpr mice by administration of an immunoglobulin-binding peptide. Nat. Biotechnol. 18, 735-739 (2000).
39. L. M. Khachigian, Collagen antibody-induced arthritis. Nat. Protoc. 1, 2512-2516 (2006).
40. M. Kasperkiewicz, F. Nimmerjahn, S. Wende, M. Hirose, H. Iwata, M. F. Jonkman, U. Samavedam, Y. Gupta, S. Möller, E. Rentz, L. Hellberg, K. Kalies, X. Yu, E. Schmidt, R. Häsler, T. Laskay, J. Westermann, J. Köhl, D. Zillikens, R. J. Ludwig, Genetic identification and functional validation of FcgRIV as key molecule in autoantibody-induced tissue injury. J. Pathol. 228, 8-19 (2012).
41. X. Li, R. P. Kimberly, Targeting the Fc receptor in autoimmune disease. Expert Opin. Ther. Targets 18, 335-350 (2014).
42. P. M. Hogarth, Fc receptors are major mediators of antibody based inflammation in autoimmunity. Curr. Opin. Immunol. 14, 798-802 (2002).
43. C. Gillis, A. Gouel-Chéron, F. Jönsson, P. Bruhns, Contribution of human FcgRs to disease with evidence from human polymorphisms and transgenic animal studies. Front. Immunol. 5, 254 (2014).
44. C. J. Bosques, A. M. Manning, Fc-gamma receptors: Attractive targets for autoimmune drug discovery searching for intelligent therapeutic designs. Autoimmun. Rev. 15, 1081-1088 (2016).
45. N. Rieth, A. Carle, M. A. Müller, D. ter Meer, C. Direnberger, T. Pohl, P. Sondermann, Characterization of SM201, an anti-hFcgRIIB antibody not interfering with ligand binding that mediates immune complex dependent inhibition of B cells. Immunol. Lett. 160, 145-150 (2014).
46. R. Shashidharamurthy, R. A. Hennigar, S. Fuchs, P. Palaniswami, M. Sherman, P. Selvaraj, Extravasations and emigration of neutrophils to the inflammatory site depend on the interaction of immune-complex with Fcg receptors and can be effectively blocked by decoy Fcg receptors. Blood 111, 894-904 (2008).
47. D. M. Czajkowsky, J. T. Andersen, A. Fuchs, T. J. Wilson, D. Mekhaiel, M. Colonna, J. He, Z. Shao, D. A. Mitchell, G. Wu, A. Dell, S. Haslam, K. A. Lloyd, S. C. Moore, I. Sandlie, P. A. Blundell, R. J. Pleass, Developing the IVIG biomimetic, Hexa-Fc, for drug and vaccine applications. Sci. Rep. 5, 9526 (2015).
48. T. W. Huizinga, F. van Kemenade, L. Koenderman, K. M. Dolman, A. E. von dem Borne, P. A. Tetteroo, D. Roos, The 40-kDa Fc gamma receptor (FcRII) on human neutrophils is essential for the IgG-induced respiratory burst and IgG-induced phagocytosis. J. Immunol. 142, 2365-2369 (1989).
49. F. Fabris, G. Luzzatto, P. M. Stefani, B. Girolami, G. Cella, A. Girolami, Heparin-induced thrombocytopenia. Haematologica 85, 72-81 (2000).
50. A. J. Antczak, N. Singh, S. R. Gay, R. G. Worth, IgG-complex stimulated platelets: A source of sCD40L and RANTES in initiation of inflammatory cascade. Cell. Immunol. 263, 129-133 (2010).
51. U. Blank, P. Launay, M. Benhamou, R. C. Monteiro, Inhibitory ITAMs as novel regulators of immunity. Immunol. Rev. 232, 59-71 (2009).
52. C. Torigoe, J. K. Inman, H. Metzger, An unusual mechanism for ligand antagonism. Science 281, 568-572 (1998).
53. Y. Kaneko, F. Nimmerjahn, J. V. Ravetch, Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313, 670-673 (2006).
54. N. Washburn, I. Schwab, D. Ortiz, N. Bhatnagar, J. C. Lansing, A. Medeiros, S. Tyler, D. Mekala, E. Cochran, H. Sarvaiya, K. Garofalo, R. Meccariello, J. W. Meador III, L. Rutitzky, B. C. Schultes, L. Ling, W. Avery, F. Nimmerjahn, A. M. Manning, G. V. Kaundinya, C. J. Bosques, Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity. Proc. Natl. Acad. Sci. U.S.A. 112, E1297-E1306 (2015).
55. Y. Shinkai, G. Rathbun, K.-P. Lam, E. M. Oltz, V. Stewart, M. Mendelsohn, J. Charron, M. Datta, F. Young, A. M. Stall, F. W. Alt, RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 68, 855-867 (1992).
56. C. Sitaru, S. Mihai, C. Otto, M. T. Chiriac, I. Hausser, B. Dotterweich, H. Saito, C. Rose, A. Ishiko, D. Zillikens, Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen. J. Clin. Invest. 115, 870-878 (2005).
57. A. Raja, U. D. Ranganathan, B. Ramalingam, Clinical value of specific detection of immune complex-bound antibodies in pulmonary tuberculosis. Diagn. Microbiol. Infect. Dis. 56, 281-287 (2006).
58. C. J. Bosques, J. S. Huston, J. C. Lansing, L. E. Ling, J. Meador, D. Ortiz, L. Rutitzky, B. C. Schultes, Compositions and methods related to engineered Fc constructs. U.S. Patent PCT/US2015/028926 (WO/2015/168643) (2015).